Product Overview
Dragon Pharma Femara is letrozole in 2.5 mg tablets. In class terms it is a non-steroidal agent that binds aromatase reversibly, one of the type II inhibitors. Inside a cycle it plays an ancillary role rather than a performance one: it adds no muscle and is taken to hold estrogen in range on a stack built from aromatising compounds. The 2.5 mg unit is the strength used in clinical labelling, where a single daily tablet is the medical dose, and every dosing step below starts from a fraction of it.
The mechanism is the reason for the caution. Letrozole attaches itself to the haem iron of aromatase and stops androgens from being turned into estrogens, so what falls is the amount of estradiol the body makes rather than receptor signalling. That distinction separates this class from a SERM such as Nolvadex, which occupies the estrogen receptor while leaving aromatase activity alone. Letrozole is the strongest of the widely used inhibitors: at 2.5 mg a day it suppresses aromatase by 98.9-99.1 percent, while compounds such as Arimidex and Aromasin are softer in routine use.
The elimination half-life is about two days, so a missed tablet does not collapse the effect immediately and the drug is normally taken at the same time each day. Because the potency is high, most of the practical work with letrozole is about restraint: the goal is the smallest dose that holds estradiol in the middle of the reference range, and the classic error is treating a 2.5 mg tablet as one unit. The axis itself is not shut down by it, so it cannot act as a recovery drug or stand in for therapy after a cycle.
Dosage Protocol
Doses below are the reference ranges for letrozole. The tablet is 2.5 mg, so quarter and half fractions are the normal working units and the intake is best moved forward by blood work rather than by a calendar.
| Beginner | 0.25-0.625 mg every other day, a quarter tablet or less, 4-6 weeks by blood work |
| Intermediate | 0.625-1.25 mg every other day for 6-8 weeks, with the dose set by the estradiol result |
| Advanced | 1.25-2.5 mg a day, by blood work; the top of the range is the medical daily dose and carries a real risk of drying joints and libido out |
| Female | 2.5 mg a day is a medical dose for ovulation induction in conditions such as PCOS, prescribed and supervised; no athletic female protocol is confirmed in the sources |
| Administration | Oral, at a consistent time of day; the 2.5 mg tablet is divided, and the schedule reflects a half-life of about two days |
Suggested Protocols
This product is used inside someone else's cycle. The combinations below show the three common roles: routine estrogen control, an emergency response to a gyno flare, and a lower-potency alternative when the letrozole response is too strong.
What to Expect
- Estrogen signs ease. Water retention and breast sensitivity linked to high estrogen usually begin to settle within several days of starting.
- A strong response. With 2.5 mg a day suppressing aromatase by 98.9-99.1 percent, the effect can be far larger than expected from a single small tablet.
- Joint dryness. Dry, aching joints and a drop in libido are the standard complaints when estrogen is driven too low, and they are reported more often with letrozole than with anastrozole.
- Blood work is the guide. An estradiol test before and during use is the only reliable way to avoid slipping into hypoestrogenia.
- The full tablet is normally too much. For daily athletic control a whole 2.5 mg tablet is almost always excessive, which is why fractions are used.
- Duration matters. Prolonged use is associated with a risk to bone density, so open-ended multi-month courses are not justified.
- No muscle effect. Nothing here builds tissue; the product only changes how much estrogen the cycle produces.
Side Effects and Management
Most of the entries below point to an estrogen level that has been driven too low, not to toxicity, and the answer is a smaller dose backed by a blood test.
Cycle Support and Follow-Up
Letrozole cannot restart natural production. Because the axis is never suppressed by it, the therapy that follows a cycle with Nolvadex or Clomid targets the cycle itself, not the inhibitor. What matters here is when to stop the inhibitor and what to test.
